Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Malika Kapadia
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05569512CT.gov Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Busulfanum (this asset) | Malika Kapadia | P2 | B · 58 |
| (+)-Vincristine | Tianjin Medical University Cancer Institute and Hospital | P2 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Nivolumab | Australian & New Zealand Children's Haematology/Oncology Group | P2 | B |
| Dexasone | Yizhuo Zhang | P3 | B |
| OTL-38 | Mayo Clinic | P3 | B |
| Epirubicin | Children's Hospital Medical Center, Cincinnati | P2 | B |
| Nivestim | St. Jude Children's Research Hospital | P2 | B |
| Ondansetron | Yizhuo Zhang | P3 | B |
+42 more in the Childhood Malignant Neoplasm cohort
Other indications for Busulfanum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Graft Versus Host Disease | — | P4 | BBB · 74 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Busulfanum in Childhood Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/busulfanum-childhood-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →